Received Jul 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | — | — |
one patient experienced a red patch with big blisters after vaccination with CAPVAXIVE; one patient experienced a red patch with big blisters after vaccination with CAPVAXIVE; This spontaneous report was received from a consumer or other non-health professional and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient was vaccinated with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) for prophylaxis (dose, route of administration, vaccination scheme frequency, anatomical location, lot number, and expiration date were not reported). On an unknown date, reported as after vaccination, the patient experienced red patch (Erythema) with big blisters (Blister). At the reporting time, the outcome of the events was unknown. The causal relationship between the events and the suspect vaccine was not reported.